'Young blood' Alzheimer's treatments slapped with warning by FDA commissioner

Treatments offering to combat dementia and other Alzheimer's Disease-related conditions with infusions of blood from young donors were slapped Tuesday by the Food and Drug Administration, prompting at least one company to cease treatments. The statement by FDA Commissioner Scott Gottlieb shines a light on the work of a handful of companies operating in the Bay Area — including at least one in human clinical trials — but focuses on "establishments in several states" that offer plasma infusions…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news